IAS 2017: Closing ceremony exposes Gilead Sciences
Conference funders, Gilead Sciences, named and shamed for its “insatiable greed” Yesterday, the 9th International AIDS Conference on HIV Science...
BLOG: We want dolutegravir for all, and we want it now
Author: Othoman Mellouk, Intellectual Property and Access to Medicines Lead at the International Treatment Preparedness Coalition (ITPC). Article first published...
HIV activists denounce ViiV for denying 3.5 million people access to optimal treatment
Today, Monday, 24 July 2017, during the 9th International AIDS Conference on HIV Science in Paris (IAS 2017), HIV treatment...
Intellectual Property Group opposes a resolution which would restrict access to medicines in Brazil
Our partner in Brazil highlights the facts in a debate full of confusion Last month, the Working Group on Intellectual...
Brazil: Open letter insists that pharmaceuticals’ interests must NOT be prioritized over public health
The Working Group on Intellectual Property responds to what it sees as ‘an attack on the rights of the Brazilian...
#TreatPeopleRight – Highlights from the ITPC Annual Review
Campaign activity contributing to combined savings of US$700 million for health budgets is among ITPC’s 2016 highlights The mission of...
Brazil: People waiting for Hep C cure caught between a life-changing decision – and an attempt to block it
Anvisa’s decision would allow the purchase of generics, and increase access to quality Hep C treatment – but a simultaneous...
Thai decision to ‘speed up’ drug patents would threaten access to medicines
Global community on access to medicines calls on Thai PM to retain a pro public health stance. The Thai...
Going to AIDS 2016? Let us know how you feel about your HIV treatment?
Happy or sad about your HIV treatment, add your picture at the Treatment Networking Zone to support our campaign to end the injustice of treatment inequality.